|
 |
AbelcetThis page contains recent news articles, when available, and an overview of Abelcet but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Enzon's specialty pharmaceutical business includes Oncaspar for leukemia, Adagen for immunodeficiency disease, DepoCyt for a type of meningitis and Abelcet ... Wall Street Journal Enzon Inc. Reports Operating Results (10-Q) - Nov 3, 2009 Enzon's specialized sales force markets ABELCET ONCASPAR ADAGEN and DEPOCYT in the United States. In addition Enzon also receives royalties on sales of ... GuruFocus.com Sigma-Tau buys specialty pharmaceuticals from Enzon - Nov 12, 2009 Enzon's specialty pharmaceutical business includes four marketed products: Abelcet, an antifungal amphotericin B liposomal injection, Adagen, ... European Biotechnology News BioWatch: Deal fits Sigma-Tau's focus on rare diseases - Nov 12, 2009 ...the "Bubble Boy Disease;" DepoCyt, a meningitis drug; and Abelcet, for treating invasive fungal infections in patients with compromised immune systems. ... Business Gazette Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals, Pfizer and ... - Nov 11, 2009 Enzon has four marketed products -- Oncaspar for the treatment of acute lymphoblastic leukemia (ALL); DepoCyt for lymphomatous meningitis; Abelcet for ... Zacks.com Baupost Initiates Enzon Position, Ups ViaSat Stake - Nov 11, 2009 The Company has a portfolio of four marketed products: Oncaspar, DepoCyt, Abelcet and Adagen. Enzon's drug development programs utilize several approaches, ... Seeking Alpha (blog) Enzon to sell specialty pharmaceutical business to Sigma-Tau - Nov 11, 2009 Enzon's specialty pharmaceutical business includes four marketed products: Oncaspar, Adagen, DepoCyt, and Abelcet, as well as the manufacturing facility in ... Trading Markets (press release) Enzon Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and ... - Nov 9, 2009 The product portfolio of the company includes Oncaspar, Depocyt, Abelcet and Adagen. The company uses its proprietry technologies including PEGylation and ... PR-Inside.com (Pressemitteilung) Sigma-Tau, shopping negli Usa - Nov 9, 2009 Il ramo d'azienda ceduto a sigma-tau da Enzon comprende quattro prodotti identificati dai seguenti marchi: Oncaspar, Adagen, DepoCyt e Abelcet, ... Il Sole 24 Ore Enzon将以3亿美元出售特ç§?è?¯ä¸šåŠ¡ - Nov 9, 2009 Sigma-tauå°†è¦?收è´çš„特ç§?è?¯ç‰©åŒ…括抗癌è?¯Oncasparã€?霉è?Œæ„ŸæŸ“治疗è?¯ç‰©Abelcetã€?脑膜炎è?¯ç‰©DepoCyt，以å?ŠAdagen，å?Žè€…被用于治疗严é‡?è?”å?ˆå…?疫缺陷(severe combined ... 新浪网 Anvisa suspende propaganda de medicamento que maquiava bula e informações médica - Nov 3, 2009 O Laboratório Bagó foi condenado pela Agência Nacional de Vigilância Sanitária (Anvisa) a suspender toda a propaganda criada para o medicamento Abelcet. ... O Repórter FARMACI: DOMPE', IMPORTANTE ACQUISIZIONE DI ENZON DA SIGMA TAU - Nov 12, 2009 ...(AGI) - Roma, 12 nov. - "Esprimo forte apprezzamento per l'acquisizione della Divisione Specialty Care di Enzon Pharmaceuticals che sara' completata dopo ... AGI - Agenzia Giornalistica Italia Tamiflu está na berlinda - Nov 4, 2009 A Agência Nacional de Vigilância Sanitária (Anvisa) concluiu a análise das reações provocadas pelo Tamiflu, medicamento usado no tratamento da gripe suÃna. ... Correio Braziliense Enzon Reports 2nd Quarter 2009 Results - Aug 4, 2009 Sales in the US and Canada of Abelcet, a lipid complex formulation of amphotericin B used primarily in the hospital to treat immuno-compromised patients FOXBusiness AXYS, ORB, INFN, ENZN, CBAN Expected To Be Higher Leading Up To ... - Jul 9, 2009 The company also offers Abelcet, a lipid formulation of amphotericin B used to treat immuno-compromised patients with invasive fungal infections; TMCnet Enzon Commences Phase II Trial of PEG-SN38 - Jun 23, 2009 The Company has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. Enzon's drug development programs utilize several PipelineReview.com (press release) BUYINS.NET: Market Maker Surveillance Report. Top 6 Winning Stocks ... - 18 Mar 2009 MYOCET, a cardio-protective chemotherapy agent to treat metastatic breast cancer; TARGRETIN for the treatment of cutaneous T-cell lymphoma; and ABELCET, Trading Markets (press release) Amgen to Present at the Cowen and Company Annual Healthcare Conference - 18 Mar 2009 Amgen (Nasdaq: AMGN) will present at the Cowen and Company Annual Healthcare Conference on Wednesday, March 18, 2009 at the Boston Marriott Copley Place, TheNewsTribune.com 10-K: ENZON PHARMACEUTICALS INC - Mar 9, 2009 We have a portfolio of four marketed products, Oncaspar, DepoCyt, Abelcet and Adagen. Our drug development programs utilize several innovative approaches, MarketWatch (press release) Enzon to Present at 29th Annual Cowen and Company Healthcare ... - Mar 16, 2009 The Company has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. Enzon’s drug development programs utilize several Earthtimes (press release) Cancer deaths and near-misses prompted drug safety review - Mar 6, 2009 The drug comes in four formulations, Abelcet, Fungizone, AmBisome and Amphocil, and recommended dosage ranges from 1 to 5mg/kg. The patient safety agency Times Online Enzon Reports 2008 Results - Feb 19, 2009 Sales in the US and Canada of Abelcet, a lipid complex formulation of amphotericin B used primarily in the hospital to treat immuno-compromised patients Trading Markets (press release) Enzon Nominates Two New Candidates for Its Board of Directors - Jan 28, 2009 Enzon has a portfolio of four marketed products, Oncaspar ® , DepoCyt ® , Abelcet ® and Adagen ® . The Company’s drug development programs utilize several WELT ONLINE, Enzon Concludes Tender Offer for a Portion of Its Debt - Jan 21, 2009 Enzon has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. The Company’s drug development programs utilize several WELT ONLINE, Enzon to Purchase a Portion of Its Outstanding Debt - Dec 5, 2008 Enzon's best-known products are Oncaspar, DepoCyt, Abelcet and Adagen. Its PEGylation technology platform not only was used to create its own Oncaspar and Scarlet Scuttlebutt, Enzon Pharmaceuticals, Inc. - SWOT Analysis - companiesandmarkets ... - Dec 9, 2008 The company currently markets Oncaspar, DepoCyt, Abelcet and Adagen. The company primarily operates in the US and Europe. It is headquartered in Bridgewater Live-PR.com (Pressemitteilung), Enzon to Purchase a Portion of Its Outstanding Debt - Dec 3, 2008 Enzon has a portfolio of four marketed products, Oncaspar ® , DepoCyt ® , Abelcet ® and Adagen ® . The Company’s drug development programs utilize several WELT ONLINE, Titan, Targeted Genetics, InSite Cut Staff; Enzon Nixes Spin-off - Dec 2, 2008 Enzon's specialty pharmaceutical business would continue to operate under the original company and would include marketed products Abelcet, Adagen, BioWorld Online, Enzon Pharmaceuticals, Inc. - SWOT Analysis - companiesandmarkets ... - Nov 19, 2008 The company currently markets Oncaspar, DepoCyt, Abelcet and Adagen. The company primarily operates in the US and Europe. It is headquartered in Bridgewater PR-Inside.com (Pressemitteilung), Enzon Reports Solid Third Quarter 2008 Results - Nov 5, 2008 Abelcet, for the treatment of invasive fungal infections, continues to exhibit relative stability in a very competitive marketplace. MarketWatch iCo Therapeutics Oral Amphotericin B Poster at AAPS - Nov 18, 2008 ...the Administration of Novel Monoglyceride-based Oral Amphotericin B Formulations and Abelcet to Rats Infected with Aspergillus Fumigatus" (Poster No. CNW Telbec (Communiqué de presse), Enzon Pharmaceuticals, Inc. - SWOT Analysis - New Research Report ... - Nov 15, 2008 It´s portfolio includes Oncaspar, DepoCyt, Abelcet and Adagen. Enzon also engages in contract manufacturing for several pharmaceutical companies. Live-PR.com (Pressemitteilung), Cephalon Inc. Q3 2008 Earnings Conference Call Transcript - Oct 28, 2008 That includes US sales of TREANDA and TRISENOX and European sales of ABELCET, MYOCET, TARGRETIN and TRISENOX. Our guidance for other sales is between $180 Seeking Alpha, Enzon's HIF-1 Alpha Antagonist Shows Antitumor Activity - Oct 27, 2008 Enzon has a portfolio of four marketed products, Oncaspar ® , DepoCyt ® , Abelcet ® and Adagen ® . The Company’s drug development programs utilize several Earthtimes (press release), Enzon to Release Third Quarter 2008 Earnings on Wednesday ... - Oct 29, 2008 Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several PR-Inside.com (Pressemitteilung), Journal de Pharmacie Clinique - Oct 30, 2008 ...pas fait l’objet de recommandation officielle ; – sont non recommandés l’amphotéricine B complexe lipidique (Abelcet ® ) et le voriconazole (Vfend ® ). Journal Pharmacie Clinique (Abonnement), Enzon Presents New Data on Its LNA Programs - 20 Oct 2008 Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several MarketWatch Enzon to Present Data at EORTC-NCI-AACR - Oct 16, 2008 Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several MarketWatch Analyst Blog Enzon Pharma Risks Balanced Aug 18, 2008 Enzon Pharmaceuticals’ (ENZN) key product Abelcet, a treatment for fungal infections, sales continued to deteriorate in 2008. Further, another major sourceZacks.com, Enzon Reports Solid Second Quarter 2008 Results - 06 Aug 2008 Sales of Abelcet® were relatively stable during the second quarter of 2008 as compared to the second quarter of 2007. The 36% increase in revenue for the Business Wire (press release), Cephalon, Inc. Q2 2008 Earnings Call - Jul 29, 2008 100 patient study of Rituximab plus TREANDA and relapsed CLL patients and the Phase 1 study combining the ABELCET and TREADA and refractory multiple myeloma Seeking Alpha, Enzon Files for Spin-off of Biotech Business - Jul 31, 2008 Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several MarketWatch Enzon Eliminates Its Remaining 2008 Debt - 02 Jul 2008 Enzon has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. The Company’s drug development programs utilize several Business Wire (press release), Enzon Pharmaceuticals, Inc. - SWOT Analysis - New Research Report ... - 02 Jul 2008 It´s portfolio includes Oncaspar, DepoCyt, Abelcet and Adagen. Enzon also engages in contract manufacturing for several pharmaceutical companies. PR-Inside.com (Pressemitteilung), Enzon to spin off biotech unit into cancer research company - May 7, 2008 Enzon will also retain rights to its currently marketed drugs, which include Oncaspar for leukemia, Depocyt for meningitis, Abelcet for fungal infections CNNMoney.com Enzon Pharma to spin off biotechnology business - May 8, 2008 Post spin-off, Enzon will retain the current marketed products of Abelcet, Adagen, DepoCyt and Oncaspar, the rights to current PEG royalty revenues, domain-B, Enzon splitting into two companies - May 7, 2008 The company's core specialty pharmaceutical business -- which markets such products as the cancer drug Oncaspar and Abelcet, a treatment for invasive fungal The Star-Ledger - NJ.com, Jack Geltosky, Ph.D. Joins Enzon's Board of Directors - May 29, 2008 Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several PharmaLive.com (press release), Enzon Announces Clinical Data from PEG-SN38 and rhMBL Studies at ASCO - May 20, 2008 Enzon has a portfolio of four marketed products, Oncaspar ® , DepoCyt ® , Abelcet ® and Adagen ® . The Company’s drug development programs utilize several Business Wire (press release), Market Report -- In Play (ENZN) - May 7, 2008 Following the spin-off of the biotechnology company, Enzon will retain the current marketed products of Abelcet, Adagen, DepoCyt and Oncaspar, the rights to MSN Money Cimzia ® , Utilizing Enzon’s Pegylation Technology, Approved in the US - 23 Apr 2008 Enzon has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. The Company's drug development programs utilize several Business Wire (press release), The SI Report: Progressive Following on Enzon Pharmaceuticals Inc. - Apr 10, 2008 Enzon has a portfolio of four marketed products, Oncaspar , DepoCyt , Abelcet and Adagen . The Company's drug development programs utilize several Trading Markets (press release), Enzon Reports Solid 2007 Results - Feb 14, 2008 Sales in the US and Canada of Abelcet, a lipid complex formulation of amphotericin B used primarily in the hospital to treat immuno-compromised patients Centre Daily Times, Enzon Pharmaceuticals to Add New Independent Director to Board - Feb 12, 2008 Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several FOXBusiness Enzon Pharmaceuticals Swings To Profit In Q4; Guides FY08 - Feb 14, 2008 Adagen and Abelcet segment generated revenues of $7.7 million and $7.4 million, respectively for the quarter, which remained flat from the year-ago quarter. RTT News, |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
